BRIEF: Kelun-Biotech raises $250 million through share placement
Innovative cancer drug company Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. (6990.HK) announced on Thursday it plans to sell 5.92 million shares through a placement, representing 2.54% of its enlarged share capital.…
CARsgen seeks cell therapy breakthrough but stays in the red for now
The developer of specialized cancer treatments is shifting from costly personalized therapy to more standardized options, but at the price of short-term financial pain Key Takeaways: The company launched its…
Cancer drug maker Genfleet joins Hong Kong IPO influx
The biotech can boast a long list of big-name backers and has brought a promising drug to the market with its partner Innovent, but its cash reserves are dwindling Key…
FAST NEWS: RemeGen scales back A-share fundraising plan
The Latest: Novel drug maker RemeGen Co. Ltd. (9995.HK; 688331.SH) announced Wednesday that it has reduced its fundraising target through a planned issue of new A-shares from a previous 2.55 billion yuan ($350…
BeiGene still bleeding red ink despite blockbuster drug
The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising Key Takeaways: The Chinese biotech reported a…
PODCAST: China’s Burgeoning Debt, and a New Type of China IPO
By Doug Young & Rene Vanguestaine China's debt-to-GDP ratio swelled to 288% last year, up 13.5 basis points and a huge level by any standard. Is this kind of debt…
FAST NEWS: Hutchmed swings to profit on strong revenue growth
The latest: Hutchmed (China) Ltd. (HCM.US; 0013.HK) announced Monday a net profit of $169 million in the first half of 2023, reversing a loss of $163 million in the same period…
